Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771235 | 0.84 | SMPD3 (0.73) | SMPD3KDM4EALDH1A1NISCHMAP3K11 | |
| SCHEMBL5803059 | 0.82 | SMPD3 (0.69) | SMPD3KDM4EALDH1A1NOX1NISCH | |
| SCHEMBL770667 | 0.79 | SMPD3 (0.66) | SMPD3KDM4EALDH1A1NISCHMAP3K11 | |
| SCHEMBL27803371 | 0.79 | SMPD3 (0.65) | SMPD3KDM4EALDH1A1NISCHMAP3K11 | |
| SCHEMBL6630552 | 0.77 | SMPD3 (0.62) | SMPD3KDM4EALDH1A1NISCH | |
| SCHEMBL12714764 | 0.76 | SMPD3 (0.60) | SMPD3KDM4EALDH1A1NISCHMAP3K11 | |
| SCHEMBL28494454 | 0.74 | NISCH (0.62) | SMPD3KDM4EALDH1A1NISCH | |
| SCHEMBL8541773 | 0.73 | SMPD3 (0.58) | SMPD3KDM4EALDH1A1NISCHMAP3K11 | |
| SCHEMBL9488696 | 0.72 | SMPD3 (0.57) | SMPD3ALDH1A1NISCH | |
| SCHEMBL27798810 | 0.72 | KDM4E (0.73) | SMPD3KDM4EALDH1A1NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0100413-B1 | METHOD AND PREPARATION FOR THE DETERMINATION OF GLUTAMIC-OXALACETIC TRANSAMINASE ACTIVITY | Roche Diagnostics GmbH (DE) | 1986-02-05 | — | — | EP | claimed |
| US-12195450-B2 | Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| EP-3917530-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS | The Johns Hopkins University (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160148-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160148-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-06 | — | — | WO | disclosed |
| US-5776714-A | USED TO REMOVE THE BIAS CAUSED BY PRESENCE OF HEMOGLOBIN IN TEST SPECIMENS | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5601994-A | Immunoassay with novel labeled drug hapten analogues | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5578457-A | QUANTITATIVE ANALYSIS | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5571682-A | REDUCING INTERFERENT BIAS SUCH AS HEMOGLOBIN | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-11-05 | — | — | US | disclosed |
| US-5565326-A | ONE STEP CHEMICAL ANALYSIS BY RECEPTOR BINDING ASSAY | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5527709-A | Immunoassays with labeled thyronine hapten analogues | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5358852-A | Binding immunoassay | EASTMAN KODAK COMPANY (US) | 1994-10-25 | — | — | US | disclosed |
| US-5330891-A | Method for detection of a nucleic acid using particulate reagent having polyoxyalkylene side chains | EASTMAN KODAK COMPANY (US) | 1994-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195450-B2 | Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors | SMPD2, SPTLC2, SGMS2 | SMPD3 8/4885KDM4E 1559/4885ALDH1A1 3995/4885 |
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | SMPD2, SPTLC2, SGMS2 | SMPD3 8/4885KDM4E 1559/4885ALDH1A1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.